Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes
After taking a look at current research, the European Medicines Agency said NAION may affect up to 1 in 10,000 people taking semaglutide
Company Announcements: Ozempic (semaglutide) approved in the US
Reuters reported earlier this week that the South African Health Products Regulatory Authority (Sahpra) has approved a generic semaglutide made by Indias Sun Pharmaceuticals and is reviewing a further 12 applications from other companies
Compounded semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)